Please login to the form below

Not currently logged in
Email:
Password:

Cyramza

This page shows the latest Cyramza news and features for those working in and with pharma, biotech and healthcare.

Baricitinib delay casts a pall over Lilly's results update

Baricitinib delay casts a pall over Lilly's results update

reliance on older products such as Trulicity (dulaglutide) for diabetes and cancer drug Cyramza (ramucirumab). ... Despite healthy growth - respectively 139% to $480m and 27% to $186m - in the second quarter, Trulicity and Cyramza are facing increasing

Latest news

  • Lilly pitches Cyramza at bladder cancer Lilly pitches Cyramza at bladder cancer

    Lilly pitches Cyramza at bladder cancer. Pharma firm is now armed with phase III data from its RANGE study. ... Eli Lilly's Cyramza took a big step toward joining immuno-oncology agents as go-to therapies for bladder cancer, after improving

  • Lilly promises solanezumab news in Alzheimer's 'before year-end' Lilly promises solanezumab news in Alzheimer's 'before year-end'

    Among these, diabetes drugs Trulicity (dulaglutide) and Jardiance (empagliflozin) both saw solid sales gains that did not however meet analysts' expectations, while lung cancer therapy Cyramza (ramucirumab) fell 12% thanks to

  • Lilly snags first approval for sarcoma drug Lartruvo Lilly snags first approval for sarcoma drug Lartruvo

    Lilly still has patent protection for the blockbuster in the US until 2022, and in the meantime needs Lartruvo and other recent launches such as Cyramza (ramucirumab) and Portrazza (necitumumab) to

  • Lilly planning 20 new launches by 2023 Lilly planning 20 new launches by 2023

    Lechleiter noted that Lilly has launched six new products in the last two years alone - including Cyramza (ramucirumab), diabetes therapies Jardiance (empagliflozin) and Trulicity (dulaglutide) and most recently Taltz (ixekizumab) for

  • Lilly's psoriasis drug Taltz cleared in Europe Lilly's psoriasis drug Taltz cleared in Europe

    Rising sales of new products such as diabetes treatments Trulicity (dulaglutide) and Basaglar (insulin glargine) and Cyramza (ramucirumab) for stomach cancer offset declines for some of Lilly's older brands, notably

More from news
Approximately 10 fully matching, plus 13 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Lars Bruening
Shaping healthcare
Bayer’s Lars Bruening talks about moving to the UK as the market works its way through a series of seismic changes...
No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...

Infographics